Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 17/20 | 0.72 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.55 |
| ▸ | F2 | P00734 | 1/20 | 0.53 |
| ▸ | F10 | P00742 | 1/20 | 0.53 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.53 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.53 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23428814 | 0.88 | KLKB1 (0.80) | KLKB1CARM1F2F10PRSS1 | |
| SCHEMBL20027770 | 0.85 | KMT2A (0.52) | KLKB1F2F10PRSS1PRSS2 | |
| SCHEMBL12361464 | 0.85 | ALDH1A1 (0.53) | KLKB1 | |
| Hydrochloric Acid SCHEMBL21854205 | 0.84 | KMT2A (0.51) | KLKB1F2F10PRSS1PRSS2 | |
| SCHEMBL4586217 | 0.84 | KLKB1 (1.00) | KLKB1CARM1F2F10PRSS1 | |
| SCHEMBL17064574 | 0.84 | KLKB1 (0.82) | KLKB1CARM1F2F10PRSS1 | |
| SCHEMBL20502767 | 0.83 | KLKB1 (0.59) | KLKB1CARM1 | |
| SCHEMBL7478179 | 0.82 | KLKB1 (0.55) | KLKB1CARM1 | |
| SCHEMBL5474167 | 0.82 | KLKB1 (0.51) | KLKB1CARM1PRSS1PRSS2PRSS3 | |
| SCHEMBL15519630 | 0.80 | GRN (0.50) | KLKB1CARM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070060589-A1 | Inhibitors of protein arginine methyl transferases | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-15 | — | — | US | disclosed |
| WO-2006069155-A2 | INHIBITORS OF PROTEIN ARGININE METHYL TRANSFERASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060589-A1 | Inhibitors of protein arginine methyl transferases | PRMT1, PRMT3, PRMT6 | KLKB1 3255/4885CARM1 20/4885F2 2641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.